Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Marijn Vlaming"'
Autor:
Gemma Moiset, Sophie Vermond, Monique Hazenoot, Rene McLaughlin, Sabrina de Munnik, Marco Guadagnoli, Sanne Holt, Marijn Vlaming
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d87669392ddd46b18ce37510d23d849f
Autor:
Gemma Moiset, Sophie Vermond, Monique Hazenoot, Rene McLaughlin, Sabrina de Munnik, Marco Guadagnoli, Marijn Vlaming, Sann Holt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ea383c9993774934b82c985557612dba
Autor:
Sophie Vermond, Benita Quist, Sabrina de Munnik, Monique Hazenoot, Madalina Avramescu, Rene McLaughlin, Gemma Moiset, Marijn Vlaming
Publikováno v:
Cancer Research. 82:5576-5576
Engineered T cell therapies such as Chimeric Antigen Receptor T cells (CAR-T) and T Cell Receptor (TCR) T cells have emerged as a promising cancer therapy. To date, four anti-CD19 CAR-T and one anti-BCMA CAR-T products have been approved by the FDA f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a55a5aef970f4c64fdc5781a71b8b2a
https://doi.org/10.1158/1538-7445.am2022-5576
https://doi.org/10.1158/1538-7445.am2022-5576
Autor:
Marco Guadagnoli, Monique Hazenoot, Gemma Moiset, Sann Holt, Sophie Vermond, Sabrina de Munnik, Rene McLaughlin, Marijn Vlaming
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCell therapies such as Chimeric Antigen Receptor T cells (CAR-T) and T Cell Receptor (TCR) T cells are immune-therapeutic approaches showing great momentum in research and the clinic. To date, four anti-CD19 CAR-T products and one anti-BCMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45983a689c0afa5573d6650161c84f87
https://doaj.org/article/ea383c9993774934b82c985557612dba
https://doaj.org/article/ea383c9993774934b82c985557612dba
Autor:
Sophie Vermond, Marijn Vlaming, Marco Guadagnoli, Rene McLaughlin, Monique Hazenoot, Sanne Holt
Publikováno v:
Cancer Research. 81:294-294
Cell therapies, such as Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) T cells, are some of the latest immune-therapeutic approaches, showing great momentum in research and now the clinic. Only recently, two anti-CD19-CAR-T products have b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bbce262b7b213bd20bba0975adac8ac
https://doi.org/10.1158/1538-7445.am2021-294
https://doi.org/10.1158/1538-7445.am2021-294
Autor:
Marijn Vlaming, Monique Hazenoot, Sophie Vermond, Rene McLaughlin, Sanne Holt, Marco Guadagnoli
Publikováno v:
Cancer Research. 81:1373-1373
Engineered T cell therapies, such as Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) T cells, but also bi-specific antibody therapies, play a major role in the field of immuno-oncology and offer great promise in becoming a new wave of highl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34b7894afec997ceb77debe25eaecb93
https://doi.org/10.1158/1538-7445.am2021-1373
https://doi.org/10.1158/1538-7445.am2021-1373
Autor:
Miranda van der Ham, Laure Grandmoursel, Armin Maier, Julia Schüler, Anne-Marie Zuurmond, Jamil Aarbiou, Ian D. Waddell, Geraldine Servant, Lieke Geerts, Jeroen DeGroot, Marijn Vlaming
Publikováno v:
Molecular Cancer Therapeutics. 18:C021-C021
New targets for cancer treatment frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery program is often lacking. In pharmacological or genetic perturbation studies using complex bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92ea5bc99bdd847689c560295d61edf5
https://doi.org/10.1158/1535-7163.targ-19-c021
https://doi.org/10.1158/1535-7163.targ-19-c021
Autor:
Umber Saleem, Ljupcho Prodanov, Xiaoping Xu, Godfrey L. Smith, Marcelo C. Ribeiro, Robert Passier, Tessa de Korte, Diogo Mosqueira, Eric I. Rossman, Berend J. van Meer, Thomas Eschenhagen, Cathy Vickers, Stefan R. Braam, Leon G.J. Tertoolen, Christine L. Mummery, Chris Denning, Ingra Mannhardt, Victor Zamora Rodriguez, Maria Hortigon, Kate Harris, Karl S.A. Firth, Arne Hansen, Peter Clements, Marijn Vlaming, Vinoj George
Publikováno v:
Journal of Pharmacological and Toxicological Methods, 88(2):0227, 238-238. Elsevier
Journal of Pharmacological and Toxicological Methods, 88, 238-238
Journal of Pharmacological and Toxicological Methods, 88, 238-238
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85a8af80e7a7196841a9bb68c299031d
https://research.utwente.nl/en/publications/inpulse-crackit-challenge-development-of-an-in-vitro-platform-using-physiologically-mature-human-induced-pluripotent-stem-cellderived-cardiomyocytes-to-screen-for-druginduced-effects-on-cardiac-contractility(2637840e-a1e7-4c9a-9261-668410be9aeb).html
https://research.utwente.nl/en/publications/inpulse-crackit-challenge-development-of-an-in-vitro-platform-using-physiologically-mature-human-induced-pluripotent-stem-cellderived-cardiomyocytes-to-screen-for-druginduced-effects-on-cardiac-contractility(2637840e-a1e7-4c9a-9261-668410be9aeb).html
Autor:
Tessa de Korte, Fleur Stevenhagen, René Wilbers, Peter Nacken, Marijn Vlaming, Petra Mulder, Stefan R. Braam
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 93:142-143
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c2c9c395810e256640f907b1578e4a1
https://doi.org/10.1016/j.vascn.2018.01.473
https://doi.org/10.1016/j.vascn.2018.01.473
Autor:
Chris Denning, Samantha Turner, Eric I. Rossman, Christine L. Mummery, Xiaoping Xu, Anthony Bahinski, Berend J. van Meer, Ana Krotenberg Garcia, Leon G.J. Tertoolen, Tessa de Korte, Peter Clements, Marijn Vlaming, Stefan R. Braam
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 99:106595
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe7a377aebbe197f5d4036ba04973b9e
https://doi.org/10.1016/j.vascn.2019.05.170
https://doi.org/10.1016/j.vascn.2019.05.170